Literature DB >> 27280497

LASS5 Interacts with SDHB and Synergistically Represses p53 and p21 Activity.

Z Jiang, F Li, Y Wan, Z Han, W Yuan, L Cao, Y Deng, X Peng, F Chen, X Fan, X Liu, G Dai, Y Wang, Q Zeng, Y Shi, Z Zhou, Y Chen, W Xu, S Luo, S Chen, X Ye, X Mo, X Wu1, Y Li2.   

Abstract

Longevity Assurance 5 (LASS5), a member of the LASS/Ceramide Synthases family, synthesizes C16-ceramide and is implicated in tumor biology. However, its precise role is not yet well understood. A yeast two-hybrid screen was performed using a human cDNA library to identify potential LASS5- interaction partners. One identified clone encodes succinate dehydrogenase subunit B (SDHB). Mammalian two-hybrid assays showed that LASS5 interacts with SDHB, and the result was also confirmed by GST pull-down and coimmunoprecipitation assays. The C-terminal fragment of SDHB was required for the interaction. LASS5 and SDHB were co-localized in COS-7 cells. LASS5 and SDHB expressions were found to be up-regulated in neuroglioma tissue. Transfection assays showed that LASS5 or SDHB expression repressed p53 or p21 reporter activity, respectively. Simultaneous LASS5 and SDHB expression resulted in stronger repression of p53 and p21 reporter activity, suggesting that LASS5 and SDHB interaction may synergistically affect transcriptional regulation of p53 and p21. Our data provide new molecular insights into potential roles of LASS5 and SDHB in tumor biology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27280497      PMCID: PMC5280074          DOI: 10.2174/1566524016666160607090012

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  43 in total

Review 1.  Function of the p53 gene: choice between life and death.

Authors:  P M Chumakov
Journal:  Biochemistry (Mosc)       Date:  2000-01       Impact factor: 2.487

2.  Paraganglioma, neuroblastoma, and a SDHB mutation: Resolution of a 30-year-old mystery.

Authors:  R Neil Schimke; Debra L Collins; Catherine A Stolle
Journal:  Am J Med Genet A       Date:  2010-06       Impact factor: 2.802

Review 3.  Testing for germline mutations in sporadic pheochromocytoma/paraganglioma: a systematic review.

Authors:  Juan P Brito; Noor Asi; Irina Bancos; Michael R Gionfriddo; Claudia L Zeballos-Palacios; Aaron L Leppin; Chaitanya Undavalli; Zhen Wang; Juan P Domecq; Gabriela Prustsky; Tarig A Elraiyah; Larry J Prokop; Victor M Montori; Mohammad H Murad
Journal:  Clin Endocrinol (Oxf)       Date:  2014-07-07       Impact factor: 3.478

4.  Structural and functional consequences of succinate dehydrogenase subunit B mutations.

Authors:  E Kim; E M Rath; V H M Tsang; A P Duff; B G Robinson; W B Church; D E Benn; T Dwight; R J Clifton-Bligh
Journal:  Endocr Relat Cancer       Date:  2015-06       Impact factor: 5.678

5.  Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer.

Authors:  Sungwoo Lee; Eijiro Nakamura; Haifeng Yang; Wenyi Wei; Michelle S Linggi; Mini P Sajan; Robert V Farese; Robert S Freeman; Bruce D Carter; William G Kaelin; Susanne Schlisio
Journal:  Cancer Cell       Date:  2005-08       Impact factor: 31.743

6.  Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations.

Authors:  Katherine A Janeway; Su Young Kim; Maya Lodish; Vânia Nosé; Pierre Rustin; José Gaal; Patricia L M Dahia; Bernadette Liegl; Evan R Ball; Margarita Raygada; Angela H Lai; Lorna Kelly; Jason L Hornick; Maureen O'Sullivan; Ronald R de Krijger; Winand N M Dinjens; George D Demetri; Cristina R Antonescu; Jonathan A Fletcher; Lee Helman; Constantine A Stratakis
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

7.  Development of pheochromocytoma in ceramide synthase 2 null mice.

Authors:  Woo-Jae Park; Ori Brenner; Aviram Kogot-Levin; Ann Saada; Alfred H Merrill; Yael Pewzner-Jung; Anthony H Futerman
Journal:  Endocr Relat Cancer       Date:  2015-06-25       Impact factor: 5.678

8.  Programmed cell death induced by ceramide.

Authors:  L M Obeid; C M Linardic; L A Karolak; Y A Hannun
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

9.  Germline SDHB mutations and familial renal cell carcinoma.

Authors:  Christopher Ricketts; Emma R Woodward; Pip Killick; Mark R Morris; Dewi Astuti; Farida Latif; Eamonn R Maher
Journal:  J Natl Cancer Inst       Date:  2008-08-26       Impact factor: 13.506

10.  AMPK inhibitor Compound C stimulates ceramide production and promotes Bax redistribution and apoptosis in MCF7 breast carcinoma cells.

Authors:  Junfei Jin; Thomas D Mullen; Qi Hou; Jacek Bielawski; Alicja Bielawska; Xiaoming Zhang; Lina M Obeid; Yusuf A Hannun; Yi-Te Hsu
Journal:  J Lipid Res       Date:  2009-06-15       Impact factor: 5.922

View more
  2 in total

1.  High expression of ceramide synthase 5 predicts a poor prognosis in gastric cancer.

Authors:  Shengjie Zhang; Yi Wang; Li Yuan; Can Hu; Zhiyuan Xu; Xiangdong Cheng
Journal:  Transl Cancer Res       Date:  2022-09       Impact factor: 0.496

2.  C16-ceramide is a natural regulatory ligand of p53 in cellular stress response.

Authors:  Baharan Fekry; Kristen A Jeffries; Amin Esmaeilniakooshkghazi; Zdzislaw M Szulc; Kevin J Knagge; David R Kirchner; David A Horita; Sergey A Krupenko; Natalia I Krupenko
Journal:  Nat Commun       Date:  2018-10-08       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.